Cipla Ltd

BSE :500087 NSE :CIPLA Sector : Pharmac..
1,461.90
Change: 7.60(0.52%)
Buy Sell SIP
52 week Low
1,317.25
52 week High
1,702.05
Day low
1,445.65
Day high
1,465.70
Prev Close
1,454.30
Open
1,456.40
6M return
-11.92%
1Y return
-0.64%
MCap(Rs. in Cr.)
1,18,065.23
Total Volume
8,04,032
Face Value : 2
Listed Since
PE Ratio

Is the price-earnings ratio for valuing a company that measures its current share price relative to its earnings per share.

P/E RATIO
23.65814
EPS

The earnings per share ratio is a portion of company's net profit allocated for each outstanding share. It is calculated by deducting preferred stock divided from the net income of the company divided by the number of outstanding shares.

EPS
61.78
PRICE/BOOK

Price-to-book ratio is used to compared the company's current market price with its book value.

PRICE/BOOK
4.16
Deliverable

These are the acutal number of shares that are traded on delivery based, meaning transfered from one person to another during the day's trade.

DELIVERABLES
63.32%
DIV YIELD.(%)

Dividend Yield measures the quantum of cash dividends paid to shareholders in a financial year relative to the market value of the per share.

DIV YIELD.(%)
0.89

Company Details

Check out the key parameters of the company to understand the financial health and stock performance

Key Level

Resistance 1
1461.62
Resistance 2
1468.93
Support 1
1442.37
Support 2
1430.43

Moving Average

20 Days
-
50 Days
-
100 Days
-
200 Days
-
Growth in 3 years

Sales
18.43%

Sales Industry Avg
17.49%

PAT
62.35%

PAT Industry Avg
38.55%

Dec 2024
( in Cr.)		Sep 2024
( in Cr.)		Jun 2024
( in Cr.)		Mar 2024
( in Cr.)		FY 2024
( in Cr.)
Sales7,072.977,051.026,693.946,163.2425,774.09
Gross Profit2,195.892,060.801,858.041,547.606,752.92
Operating Profit00000
Profit Before Tax1,921.411,765.021,607.561,445.535,701.90
Tax337.69459431.27511.131,546.59
Profit After Tax1,583.721,306.021,176.29934.404,155.31
Growth in 3 years

Total Asset Growth
23.17%

Total Liabilities growth
23.17%

Reserves Change
28.36%

Mar 2024
( in Cr.) 		Mar 2023
( in Cr.) 		Mar 2022
( in Cr.) 		Mar 2021
( in Cr.) 		Mar 2019
( in Cr.)
Share Capital161.47161.43161.36161.29161.14
Reserves And Surplus26,544.9623,246.3520,680.3318,165.2414,851.14
Investments5,449.223,662.382,550.602,710.052,554.14
Total Debt818.421,071.091,307.832,292.324,908.40
Total Liabilities27,620.7524,784.6322,425.2120,877.9120,252.65
Total Assets27,620.7524,784.6322,425.2120,877.9120,252.65
425%
2023
650%
2024 2025
2026


Relative to Sensex rtn in 3 year
28.35%

Relative to Nifty rtn in 3 year
20.32%



1 Year (%)2 Year (%)3 Year (%)
Cipla-16739
Bse Sensex02731
Nifty 5023133
Nifty 50034040

Peer Companies

A quick glance on how stocks from the same sector have performed along with some key parameters

Cipla
1,461.90
Change: 7.60 (0.52%)
1 Year return
-0.64%
Risk (Std Dev)
0.04%
PE Ratio
23.65814
MCap( in Cr.)
1,18,065.23
BUY SELL
Sun Pharma.Inds.
1,683.45
Change: 6.60 (0.39%)
1 Year return
8.01%
Risk (Std Dev)
0.07%
PE Ratio
34.25244
MCap( in Cr.)
4,03,916.05
BUY SELL
Divi`s Lab.
5,620.45
Change: -46.70 (-0.82%)
1 Year return
61.52%
Risk (Std Dev)
0.06%
PE Ratio
72.17827
MCap( in Cr.)
1,49,205.29
BUY SELL
Torrent Pharma.
3,056.05
Change: -40.45 (-1.31%)
1 Year return
14.72%
Risk (Std Dev)
0.06%
PE Ratio
55.58797
MCap( in Cr.)
1,03,425.97
BUY SELL
Dr Reddy`s Labs
1,107.95
Change: 2.80 (0.25%)
1 Year return
-12.12%
Risk (Std Dev)
0.08%
PE Ratio
17.21066
MCap( in Cr.)
92,452.24
BUY SELL
View More

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

 

If I had made
investment of  
in
Months Ago
My investment would be worth 99,364.50 with a Loss of -0.64%

Our Research Reports

Stocks and sector-wise Research Reports by HDFC securities help you analyse, understand and take a informed investment decision.

Institutional Reports 26 Jan 2022 7:53 AM
HSIE Results Daily: Cipla, Torrent Pharma, Shriram Transport Finance Company, Supreme Industries, APL Apollo, Federal Bank, IndiaMART InterMESH, Zensar Technologies, Teamlease Services, Sudarshan Chemical, Deccan Cements
Cipla: Cipla’s Q3 results came largely in line with our estimates as strong growth trends in India and the US were partially offset by weak performance in other markets. India business continues to r..
Institutional Reports 28 Oct 2021 7:15 AM
HSIE Results Daily: ITC, Larsen & Toubro, Maruti Suzuki, SBI Life Insurance, IndusInd Bank, Cipla, Torrent Pharma, ABB India, Persistent Systems, TTK Prestige, Zensar Technologies, Mahanagar Gas, Mahindra Lifespaces, PSP Projects
ITC: ITC delivered an in-line revenue growth with a few positives in key segments. Revenue was up 12% YoY with cigarettes/FMCG/hotels/agri/paper growing 10/6/260/-7/25% YoY. Cigarette revenue growth ..
Institutional Reports 27 Oct 2021 9:10 AM
Cipla (Results Review 2QFY22): In-line quarter; upbeat on outlook. Maintain BUY
Cipla’s Q2 results were largely in line with estimates as strong growth trends in India, South Africa, and EM markets were partially offset by lower gross margin (~80-100bps impact, inventory provisi..
View More

Corporate Action

Find out the historical dividend payout and other corporate actions including bonus, stock split and rights issue etc.

D
2023
D
2024
2025

Our Research Analysis

Created with Highstock 5.0.7Values19. Aug2. Sep16. Sep30. Sep14. Oct28. Oct11. Nov25. Nov9. Dec23. Dec6. Jan20. Jan3. Feb17. Feb3. Mar13501400145015001550160016501700
As of today
0%
Target Achived
This call still has potential to give significant positive returns

Potential Upside
24.43%
Buy Call with 3 QUARTER(s) time frame
CMP : 1461.90
Target : 1819
Stop Loss : 0
Reco Price : 1576.10
Reco Date :19 Aug 2024
Call Type :PICK OF THE WEEK


FnO

A snapshot on how the stock has performed in the derivatives segment on a real-time basis.

Cipla Ltd 1,460.85 Chg: 3.05(0.21%) Expiry Month 27 Mar 2025
Day's Low
1,449.40
Day's High
1,467.30
Day’s Open
1,457.00
Prev Close
1,457.80
Volume
7,09,150
OI
1,12,84,325
OI Change (%)
-1.07
View More

News

Stay tuned to the latest developments and happenings in the company.

USFDA classifies cGMP inspection of Cipla`s Virgonagar facility as VAI

Cipla has classified its current Good Manufacturing Practices (cGMP) inspection of the company`s manufacturing facility in Virgonagar, Bengaluru, cond....

08 Feb 2025 11:16

Cipla to infuse ZAR 900 million in Cipla Medpro South Africa Proprietary Limited

Cipla will invest approx. ZAR 900 million in equity share capital of Cipla Medpro South Africa Proprietary Limited, a wholly-owned subsidiary of the C....

03 Feb 2025 19:20

Cipla consolidated net profit rises 48.74% in the December 2024 quarter

Net profit of Cipla rose 48.74% to Rs 1570.51 crore in the quarter ended December 2024 as against Rs 1055.90 crore during the previous quarter ended D....

28 Jan 2025 16:57

Cipla to table results

Cipla will hold a meeting of the Board of Directors of the Company on 28 January 2025.Powered by Capital Market - Live News

07 Jan 2025 10:09

Cipla consolidated net profit rises 15.18% in the September 2024 quarter

Net profit of Cipla rose 15.18% to Rs 1302.53 crore in the quarter ended September 2024 as against Rs 1130.91 crore during the previous quarter ended ....

29 Oct 2024 15:32

Cipla consolidated net profit rises 18.27% in the June 2024 quarter

Net profit of Cipla rose 18.27% to Rs 1177.64 crore in the quarter ended June 2024 as against Rs 995.70 crore during the previous quarter ended June 2....

26 Jul 2024 16:06

View More
Subscribe for our
newsletter
Open Account Now